

under control number 0910–0014. The information collection described in the guidance for industry entitled “Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products” is approved by OMB under control number 0910–0429. The information collection described in the guidance for industry entitled “Formal Dispute Resolution: Sponsor Appeals Above the Division Level” (available at <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM343101.pdf>) is approved by OMB under control number 0910–0430. The information collection described in the “Evaluation of the Program for Enhanced Review Transparency and Communication for New Molecular Entity New Drug Applications and Original Biologics License Applications in Prescription Drug User Fee Acts” is approved by OMB under control number 0910–0746. The information collection described in the guidance for industry entitled “Expedited Programs for Serious Conditions—Drugs and Biologics” (available at <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf>) is approved by OMB under control number 0910–0765. The information collection described in the guidance for industry entitled “Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants” (available at <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM345649.pdf>) is approved by OMB under control number 0910–0802.

### III. Electronic Access

Persons with access to the internet may obtain the guidance at <https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>, <https://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm>, or <https://www.regulations.gov>.

Dated: December 19, 2017.

**Leslie Kux,**

*Associate Commissioner for Policy.*

[FR Doc. 2017–28139 Filed 12–28–17; 8:45 am]

**BILLING CODE 4164–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Meeting of the Advisory Committee on Minority Health

**AGENCY:** Office of Minority Health, Office of the Secretary, Department of Health and Human Services.

**ACTION:** Notice of meeting.

**SUMMARY:** As stipulated by the Federal Advisory Committee Act, the Department of Health and Human Services (HHS) is hereby giving notice that the Advisory Committee on Minority Health (ACMH) will hold a meeting. This meeting will be open to the public. Preregistration is required for both public attendance and comment. Any individual who wishes to attend the meetings and/or participate in the public comment session should email [OMH-ACMH@hhs.gov](mailto:OMH-ACMH@hhs.gov). Information about the meeting is available from the designated contact and will be posted on the website for the Office of Minority Health (OMH), [www.minorityhealth.hhs.gov](http://www.minorityhealth.hhs.gov). Information about ACMH activities can be found on the OMH website under the heading *About OMH*.

**DATES:** The meeting will be held on Monday, March 26, 2018, from 9:00 a.m. to 5:00 p.m. and Tuesday, March 27, 2018, from 9:00 a.m. to 1:00 p.m.

**ADDRESSES:** The meeting will be held at the 5600 Fishers Lane Building, Room 05E29, 5600 Fishers Lane, Rockville, Maryland 20857.

**FOR FURTHER INFORMATION CONTACT:** Dr. Minh Wendt, Designated Federal Officer, Advisory Committee on Minority Health, Office of Minority Health, Department of Health and Human Services, Tower Building, 1101 Wootton Parkway, Suite 600, Rockville, Maryland 20852. Phone: 240–453–8222; fax: 240–453–8223; email [OMH-ACMH@hhs.gov](mailto:OMH-ACMH@hhs.gov).

**SUPPLEMENTARY INFORMATION:** In accordance with Public Law 105–392, the ACMH was established to provide advice to the Deputy Assistant Secretary for Minority Health on improving the health of each racial and ethnic minority group and on the development of goals and specific program activities of the OMH.

The topics to be discussed during this meeting will include strategies to improve the health of racial and ethnic minority populations through the development of health policies and programs that will help eliminate health disparities with an emphasis on serious mental illness. The recommendations will be given to the Deputy Assistant Secretary for Minority Health.

Public attendance at this meeting is limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the designated contact person at least fourteen (14) business days prior to the meeting. Members of the public will have an opportunity to provide comments at the meeting. Public comments will be limited to three minutes per speaker. Individuals who would like to submit written statements should mail or fax their comments to the Office of Minority Health at least seven (7) business days prior to the meeting. Any members of the public who wish to have printed material distributed to ACMH committee members should submit their materials to the Designated Federal Officer, ACMH, Tower Building, 1101 Wootton Parkway, Suite 600, Rockville, Maryland 20852, prior to close of business on Monday, March 19, 2018.

Dated: December 22, 2017.

**Minh Wendt,**

*Designated Federal Officer, Advisory Committee on Minority Health.*

[FR Doc. 2017–28161 Filed 12–28–17; 8:45 am]

**BILLING CODE 4150–29–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel; AIDS Research Review Committee (AIDSRRRC) Independent SEP.

*Date:* January 18, 2018.

*Time:* 1:00 p.m. to 2:00 p.m.

*Agenda:* To review and evaluate grant applications.